Consequences of Amyloid-β Deficiency for the Liver

Area of Science:

• Hepatology
• Neuroscience
• Molecular Biology

Background:

• Hepatic amyloid beta (Aβ) levels decrease in cirrhosis, yet its liver function remains unclear.
• Anti-amyloid beta (Aβ) therapies for Alzheimer's disease (AD) may impact liver Aβ levels.

Purpose of the Study:

• To investigate the role of hepatic Aβ in liver fibrosis and injury.
• To determine if Aβ influences liver cell-cell interactions and disease progression.

Main Methods:

• Utilized transgenic AD mice, amyloid precursor protein knockout (APP-KO) mice, and human liver spheroids.
• Administered Aβ antibody 3D6, neprilysin inhibitor LBQ657, and carbon tetrachloride (CCl4).
• Performed transcriptomic analysis to assess molecular changes.

Main Results:

• Aβ deficiency in the liver upregulated fibrosis markers (alpha-smooth muscle actin, collagen type I), TGFβ, NOTCH pathway, and inflammation.
• Increased hepatic Aβ42 levels protected against CCl4-induced liver injury.
• Aβ42 modulated mitochondrial function, lipid metabolism, and exhibited onco-suppressive effects in the liver.

Conclusions:

• Hepatic Aβ is an indispensable regulator of liver cell-cell interactions.
• Aβ acts as a potent protector against liver fibrosis and injury.